JCN037 manufacturers
- JCN037
-
- $48.00
-
2026-08-01
- CAS:2305154-31-6
- Purity: 99.50%
- Supply Ability: 10g
|
| Product Name: | JCN037 | | Synonyms: | JCN037;[1,4]Dioxino[2,3-g]quinazolin-4-amine, N-(3-bromo-2-fluorophenyl)-7,8-dihydro-;JCN037,Epidermal growth factor receptor,HER1,Inhibitor,JCN-037,JCN 037,inhibit,EGFR,JGK-037,ErbB-1,JGK037,JGK 037;N-(3-Bromo-2-fluorophenyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine;JCN037, 10 mM in DMSO | | CAS: | 2305154-31-6 | | MF: | C16H11BrFN3O2 | | MW: | 376.18 | | EINECS: | | | Product Categories: | | | Mol File: | 2305154-31-6.mol |  |
| | JCN037 Chemical Properties |
| Boiling point | 466.1±45.0 °C(Predicted) | | density | 1.669±0.06 g/cm3(Predicted) | | solubility | DMSO:250.0(Max Conc. mg/mL);664.57(Max Conc. mM) | | pka | 5.55±0.20(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | JCN037 Usage And Synthesis |
| Uses | JCN037 (JGK037) is non-covalent and BBB-penetrant EGFR tyrosine kinase inhibitor, with IC50 values of 2.49 nM, 3.95 nM, 4.48 nM for EGFR, p-wtEGFR and pEGFRvⅢ, respectively[1]. | | in vivo | JCN037 (compound 5) exhibits low oral bioavailability due to a rapid hydroxylation of the fused 1,4-dioxane ring, suggesting first pass metabolism[1].
JCN037 (compound 5, 300 mg/kg, BID) treatment provides a significant survival benefit, whereby median survival increased by 47% from 37.5 days to 55 days with 5 treatment[1].
| | References | [1] Jonathan E. Tsang, et al. Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors. ACS Med. Chem. Lett. 2020. May 1. |
| | JCN037 Preparation Products And Raw materials |
|